1. BMY's performance is lagging amidst broader healthcare stagnation. 2. Its major drugs face declining sales and patent expiration risks. 3. Recent partnerships and innovations may stabilize future performance. 4. BMY shares are considered undervalued with a 5.3% dividend yield. 5. Healthcare stock market pressures highlight policy uncertainties in pharma.
BMY's recent performance is down 25% over five years, indicating sustained weakness. Historical patterns show that prolonged underperformance can deter investor appetite.
The structural challenges facing BMY in the pharmaceutical market are critical for future performance. Insights into dividend yield and patent risks directly affect investor perception.
As patent expirations approach and drug sales decline, BMY may struggle to recover. Recovery in stock price may take years as new products roll out.